Lan Shen, MD; Bimal R. Shah, MD, MBA; Eric M. Reyes, Ph.D.; Laine Thomas, Ph.D.; Peter Diem, MD; Lawrence A. Leiter, MD; Bernard Charbonnel, MD; Viacheslav.

Slides:



Advertisements
Similar presentations
Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.
Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results
Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.
Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.
Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Rury R. Holman, MB, ChB, FRCP Professor of Diabetic Medicine Director, Diabetes.
The Diabetes Prevention Program 10 Year follow-up Long-term Follow-up to A Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Effect of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy versus ARB plus Calcium Channel Blocker Combination on Cardiovascular Events in Japanese.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Jacqueline Saw, MD*, Danielle Brennan, MS †, Steven Steinhubl, MD ‡, Deepak L. Bhatt, MD †, Koon-Hou Mak, MD §, Keith Fox, MB^, and Eric J. Topol, MD #
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Diagnosis of diabetes. Diabetic symptoms Diabetic symptoms + venous sample for : –Random venous ≥ 11.1 mmol/l ( ) –Fasting glucose > 7(
Thomas S. Rector, PhD, Inder S. Anand, MD, David Nelson, PhD, Kristine Ensrud, MD and Ann Bangerter, MS CHF QUERI NETWORK November 8, 2007 VA Medical Center,
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Background Current guideline recommend an early invasive strategy for NSTEMI patients (Class IIA). However, 67% US hospitals have no catheterization capability.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
A Diabetes Outcome Progression Trial
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Trends in the Quality of Care of Patients with Acute Myocardial Infarction: The National Registry of Myocardial Infarction from 1990 to 2006 Bimal R. Shah,
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (HOPE-3 trial) R4. 박은지 / PF. 정혜문 Salim Yusuf, M.B., B.S., D.Phil.,
Carina Signori, D.O., M.P.H. Penn State Hershey Medical Center Ceriello, Antonio. Diabetes Care August 2010;33,8.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
R2. 하효정 / 이상열 교수님 NEJM Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel.
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial J Am Coll Cardiol 2007;50:291-5 Jacqueline Saw, MD*, Danielle Brennan, MS†,
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
RAAS Blockade: Focus on ACEI
with type 2 diabetes without heart failure?
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The Hypertension in the Very Elderly Trial (HYVET)
Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA Trial Dr Ajay K Gupta International Centre for Circulatory.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Presentation transcript:

Lan Shen, MD; Bimal R. Shah, MD, MBA; Eric M. Reyes, Ph.D.; Laine Thomas, Ph.D.; Peter Diem, MD; Lawrence A. Leiter, MD; Bernard Charbonnel, MD; Viacheslav Mareev, MD; Edward Horton, MD; Steven M. Haffner, MD; Vladimir Soska, MD; Rury Holman, MD; Angelyn Bethel, MD; Frank Schaper, MD; Jie Lena Sun, MS; John McMurray, MD; Robert Califf, MD; Henry Krum, MBBS, Ph.D. Diuretics, Beta-blockers and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance: Insights from the NAVIGATOR study

Disclosures L. Shen: None. B. Shah: None. E. Reyes: None. L. Thomas: None. P. Diem: Research Grant; Significant; Novartis. Consultant/Advisory Board; Modest; Novartis.L. Leiter: Research Grant; Significant; Novartis. Consultant/Advisory Board; Modest; Novartis. B. Charbonnel: Consultant/Advisory Board; Modest; Novartis. V. Mareev: Speakers Bureau; Modest; Novartis. Consultant/Advisory Board; Modest; Novartis. E. Horton: Consultant/Advisory Board; Modest; Novartis. S. Haffner: None. V. Soska: None. R. Holman: Research Grant; Significant; Novartis. Consultant/Advisory Board; Modest; Novartis. M. Bethel: Research Grant; Modest; Novartis, Bayer, Merck, Amylin, Lilly. F. Schaper: Research Grant; Significant; Novartis. J. Sun: None. J. McMurray: Other; Modest; Employer (Glasgow University) paid for time as member of executive committee of NAVIGATOR and travel and accommodations for NAVIGATOR executive/steering committee meetings. R. Califf: Research Grant; Significant; Novartis. Consultant/Advisory Board; Modest; Novartis. H. Krum: Research Grant; Significant; Novartis.

Background Diuretics, β-blockers, and statins are the cornerstone of therapy in patients with CVD Even with their robust evidence of benefit, more recent data suggests that the long-term use may increase fasting glucose levels These concerns have led the US FDA to mandate a label change for statins in 2012 However, there are limited large scale studies using serial glucose measures that have linked these medications to new onset diabetes (NOD)

Objective To examine the association of new onset diabetes (NOD) with the initiation of β- blockers, thiazide diuretics, or statins in high risk, treatment naïve patients.

NAVIGATOR Study A multinational, randomized design study testing the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes Study population is 9518 patients with impaired glucose tolerance (IGT) and at least one other CV risk factor enrolled between January 4, 2002 to January 29, NAVIGATOR excluded patients with diabetes at baseline

Methods Therefore, we evaluated treatment initiation of the following medications on naïve patients. β-blockers Diuretics Statins CCBs – (metabolically negative control) Median follow-up time: 5.0 years

Methods Endpoint: New onset diabetes (NOD) NOD defined as: Fasting plasma glucose >126 mg/dl (7.0mmol/L) OR Glucose level >200 mg/dl (11.1 mmol/L) 2 hours after OGTT AND Confirmed by OGTT 12 weeks after the elevated glucose value was recorded Glucose testing frequency: Fasting plasma glucose level was measured every 6 months for the first 3 years and then annually Oral glucose tolerance tests were performed annually

Methods We examined the timing of the starting of each medication during study period We estimated the effect of receiving treatment on progression to NOD using Marginal Structural Models –In short, this is a Cox Proportional Hazard model adjusting cofounders that change over time –We present a single hazard ratio for treatment that represents the difference in rate of progression to NOD between someone who receives these medications and someone who does not

Results N=5637N=6343N=6143N=6290 Medication Initiation

Results Baseline Characteristics β –blockersDiureticsStatins Yes n=993 No n=4644 Yes n=1425 No n=4918 Yes n=1474 No n=4669 Age (Median) Hypertension (%) Congestive Heart Failure (%) Hx CV events (%) Hx stroke (%) Hx Heart Failure (%) Fasting Glucose HbA1c5.8

Results Incidence of New Onset Diabetes Unadjusted HR (95% CI) Adjusted HR (95% CI) Diuretics 1.48 (1.30,1.68) 1.35 (1.12,1.61) Statins 1.38 (1.21, 1.57) 1.30 (1.09, 1.55) β-blockers 1.35 (1.16, 1.57) 1.19 (0.97,1.46) CCBs 1.31 (0.97, 1.31) 1.14 (0.91, 1.42)

Limitations Post-hoc analysis of a clinical trial so residual confounders cannot be excluded No information on dose-response for medication No information on the adherence to specified medication Small size of population in β-blocker subgroup contributes to the limited power of the association in the β-blocker subgroup

Conclusion In high-risk patients with IGT, the use of diuretic and statin therapy is associated with NOD β-blocker therapy has a borderline effect towards the development of NOD, but the effect was not significant after adjustment Surveillance of glucose levels should be considered in high risk patients taking these medications Future studies are warranted to examine net benefit/risk profile of those medications in high risk CVD patients

Thank you